|
1
|
Suffian IM, Wang JTW, Faruqu FN, Benitez J, Nishimura Y, Ogino C, Kondo A, Al-Jamal KT. Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B Virus Core Nanoparticles for siRNA Delivery in Vitro and in Vivo. ACS APPLIED NANO MATERIALS 2018; 1:3269-3282. [PMID: 30613831 PMCID: PMC6312360 DOI: 10.1021/acsanm.8b00480] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 06/04/2018] [Indexed: 05/10/2023]
Abstract
Hepatitis B virus core (HBc) particles acquire the capacity to disassemble and reassemble in a controlled manner, allowing entrapment and delivery of drugs and macromolecules to cells. HBc particles are made of 180-240 copies of 21 kDa protein monomers, assembled into 30-34 nm diameter icosahedral particles. In this study, we aimed at formulating HBc particles for the delivery of siRNA for gene silencing in vitro and in vivo. We have previously reported recombinant HBc particles expressing ZHER2 affibodies, specifically targeting human epidermal growth receptor 2 (HER2)-expressing cancer cells (ZHER2-ΔHBc). siRNA was encapsulated within the ZHER2-ΔHBc particles following disassembly and reassembly. The ZHER2-ΔHBc-siRNA hybrids were able to secure the encapsulated siRNA from serum and nucleases in vitro. Enhanced siRNA uptake in HER2-expressing cancer cells treated with ZHER2-ΔHBc-siRNA hybrids was observed compared to the nontargeted HBc-siRNA hybrids in a time- and dose-dependent manner. A successful in vitro polo-like kinase 1 (PLK1) gene knockdown was demonstrated in cancer cells treated with ZHER2-ΔHBc-siPLK1 hybrids, to levels comparable to commercial transfecting reagents. Interestingly, ZHER2-ΔHBc particles exhibit intrinsic capability of reducing the solid tumor mass, independent of siPLK1 therapy, in an intraperitoneal tumor model following intraperitoneal injection.
Collapse
Affiliation(s)
- Izzat
F. M. Suffian
- Institute
of Pharmaceutical Science, King’s
College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
| | - Julie T.-W. Wang
- Institute
of Pharmaceutical Science, King’s
College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
| | - Farid N. Faruqu
- Institute
of Pharmaceutical Science, King’s
College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
| | - Julio Benitez
- Institute
of Pharmaceutical Science, King’s
College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
| | - Yuya Nishimura
- Department
of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan
| | - Chiaki Ogino
- Department
of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan
| | - Akihiko Kondo
- Department
of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan
| | - Khuloud T. Al-Jamal
- Institute
of Pharmaceutical Science, King’s
College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
- K.T.A.-J. Tel: +44(0)20-7848-4525. E-mail:
| |
Collapse
|
|
2
|
Schmidt U, Günther C, Rudolph R, Böhm G. Protein and peptide delivery via engineered polyomavirus-like particles. FASEB J 2001; 15:1646-8. [PMID: 11427514 DOI: 10.1096/fj.00-0645fje] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- U Schmidt
- Institut für Biotechnologie, Martin-Luther-Universität Halle-Wittenberg, 06120 Halle (Saale), Germany
| | | | | | | |
Collapse
|